1) EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1
2) NCCN Guidelines Version 3.2018 Bladder Cancer
3) Chang SS, Boorjian SA, Chou R, et al : Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer : AUA/SUO Guideline. J Urol 196 : 1021─1029, 2016
4) Yoder BJ, Skacel M, Hedgepeth R, et al : Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology : a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 127 : 295─301, 2007
5) Sarosdy MF, Schellhammer P, Bokinsky G, et al : Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168 : 1950─1954, 2002
6) Seideman C, Canter D, Kim P, et al : Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer : does FISH positivity anticipate recurrence? World J Urol 33 : 1309─1313, 2015
7) Kipp BR, Karnes RJ, Brankley SM, et al : Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 173 : 401─404, 2005
8) Whitson J, Berry A, Carroll P, et al : A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int 104 : 336─339, 2009
9) Mengual L, Marín-Aguilera M, Ribal MJ, et al : Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy. Eur Urol 52 : 752─759, 2007
10) Savic S, Zlobec I, Thalmann GN, et al : The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. Int J Cancer 124 : 2899─2904, 2009
11) Kamat AM, Dickstein RJ, Messetti F, et al : Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer : results of a prospective trial. J Urol 187 : 862─867, 2012
12) Liem EIML, Baard J, Cauberg ECC, et al : Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer. Med Oncol 34 : 172, 2017